Graft-Versus-Host Disease trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Graft-Versus-Host Disease. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month2 studies across 2 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNCT07726914AUClast | Phase 1 | Not yet recruiting | 2026-09-28 | in 39 d | 2026-07-24 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDNCT06843408Number of participants with Treatment-emergent Adverse Events (TEAEs) | Phase 1/2 | Active, not recruiting | 2027-01-06 | in 139 d | 2026-08-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Graft-Versus-Host Disease
most recently updated first38 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNY | Sanofi | — | A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseNCT07771439Overall response rate | Phase 3 | Not yet recruiting | Drug: Belumosudil · Other: Best available therapy (BAT) | Chronic Graft Versus Host Disease | 356 | 2026-09-07 | 2029-09-14 | in 1,121 d | 2026-08-18 |
| INCY | Incyte Corporation | $24.7B | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDNCT06843408Number of participants with Treatment-emergent Adverse Events (TEAEs) | Phase 1/2 | Active, not recruiting | Drug: INCA034176 | Chronic Graft-versus-host-disease | 32 | 2025-06-25 | 2027-01-06 | in 139 d | 2026-08-10 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseNCT06585774Event Free Survival (EFS) | Phase 3 | Recruiting | Drug: INCA034176, Placebo, Corticosteroids | Chronic Graft-versus-host-disease | 240 | 2025-01-21 | 2027-09-28 | in 404 d | 2026-08-06 |
| SNY | Sanofi | — | Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNCT07726914AUClast | Phase 1 | Not yet recruiting | Drug: Belumosudil, Belumosudil | Chronic Graft Versus Host Disease | 58 | 2026-08-06 | 2026-09-28 | in 39 d | 2026-07-24 |
| INCY | Incyte Corporation | $24.7B | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibNCT04640025Treatment Emergent Adverse Events (TEAE's) | Phase 2 | Terminatedsponsor's stated reason: The decision to close the study was made due to the expiration of remaining drug supply. | Drug: itacitinib | Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease | 18 | 2021-03-10 | 2026-05-11actual | — | 2026-06-26 |
| SNDX | Syndax Pharmaceuticals | $1.8B | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)NCT04710576results2024-10-10Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Recruiting | Drug: Axatilimab | Chronic Graft-versus-host-disease | 296 | 2021-03-04 | 2023-04-07actual | — | 2026-06-16 |
| SNY | Sanofi | — | A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)NCT07116031Phase 1: AUC | Phase 2 | Recruiting | Drug: Belumosudil, Belumosudil | Chronic Graft Versus Host Disease | 37 | 2025-12-02 | 2028-09-25 | in 767 d | 2026-06-05 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)NCT07124078Objective Response (OR) at 6 months | Phase 2 | Recruiting | Drug: INCA034176, Best available Treatment (BAT) | Chronic Graft-versus-host-disease | 60 | 2026-05-20 | 2029-01-31 | in 895 d | 2026-06-02 |
| SNY | Sanofi | — | A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic TherapiesNCT06616415Plasma concentrations of belumosudil at specified time points | Phase 4 | Completed | Drug: Belumosudil | Chronic Graft Versus Host Disease | 6 | 2024-12-04 | 2026-05-12actual | — | 2026-05-27 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseNCT06388564Objective Response Rate | Phase 2 | Active, not recruiting | Drug: Axatilimab, Ruxolitinib, Corticosteroids | Chronic Graft-versus-host-disease | 130 | 2024-10-11 | 2027-06-01 | in 285 d | 2026-05-22 |
| INCY | Incyte Corporation | $24.7B | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)NCT06615050GVHD-free survival (GFS) | Phase 3 | Recruiting | Drug: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF) | Graft-versus-host Disease (GVHD) | 572 | 2025-04-02 | 2031-01-17 | in 1,611 d | 2026-05-20 |
| SNY | Sanofi | — | A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)NCT07135973Drug related Grade ≥ 3 treatment emergent adverse events (TEAE) | Phase 4 | Not yet recruiting | Drug: Belumosudil | Chronic Graft Versus Host Disease | 26 | 2026-08-10 | 2027-08-30 | in 375 d | 2026-05-12 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyNCT06821542Objective Response (OR) at 6 months | Phase 3 | Active, not recruiting | Drug: INCA034176, Best Available Therapy (BAT) | Chronic Graft-versus-host-disease | 9 | 2025-06-04 | 2028-05-31 | in 650 d | 2026-03-23 |
| INCY | Incyte Corporation | $24.7B | Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsNCT03721965results2023-02-21Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated due to insufficient efficacy in a separate phase III study | Drug: Itacitinib, Corticosteroids | Acute Graft-versus-host Disease | 2 | 2019-12-31 | 2020-02-17actual | — | 2025-11-04 |
| MESO | Mesoblast, Inc. | — | Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD ParticipantsNCT00284986Response by Day 28 | Phase 2 | Completed | Drug: Prochymal | Graft Versus Host Disease | 11 | 2005-11-18 | 2006-04-25actual | — | 2025-10-30 |
| INCY | Incyte Corporation | $24.7B | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseNCT03584516results2025-01-27Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) | Phase 2/3 | Terminatedsponsor's stated reason: The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision. | Drug: Itacitinib, Placebo, Methylprednisolone, Prednisone | Chronic Graft-versus-host Disease | 155 | 2019-01-17 | 2023-11-03actual | — | 2025-10-20 |
| SNY | Sanofi | — | A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.NCT06143891Event-Free Survival (EFS) | Phase 3 | Active, not recruiting | Drug: Belumosudil, Placebo, Prednisone, Prednisolone | Chronic Graft Versus Host Disease | 260 | 2024-01-23 | 2028-09-29 | in 771 d | 2025-10-14 |
| SNDX | Syndax Pharmaceuticals | $1.8B | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHDNCT03604692results2024-11-27Phase 1: Number of Participants With DLTs | Phase 1/2 | Completed | Drug: axatilimab | Chronic Graft-versus-host-disease | 41 | 2018-11-01 | 2022-08-12actual | — | 2025-09-15 |
| INCY | Incyte Corporation | $24.7B | GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseNCT03139604results2020-05-15Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index | Phase 3 | Completed | Drug: Itacitinib, Placebo, Prednisone, Methylprednisolone | Graft-versus-host Disease (GVHD) | 439 | 2017-07-19 | 2019-05-02actual | — | 2025-09-02 |
| INCY | Incyte Corporation | $24.7B | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)NCT03112603results2022-04-15Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit | Phase 3 | Completed | Drug: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib | Graft-versus-host Disease (GVHD) | 330 | 2017-06-29 | 2020-05-08actual | — | 2025-08-12 |
| EQ | Equillium | $149M | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)NCT05263999The efficacy of itolizumab versus placebo as initial therapy for aGVHD in combination with corticosteroids in achieving early disease response. | Phase 3 | Terminatedsponsor's stated reason: The FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway based on the EQUATOR study data. | Biological: Itolizumab · Drug: EQ001 Placebo | Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD | 158 | 2022-04-29 | 2025-04-22actual | — | 2025-06-17 |
| INCY | Incyte Corporation | $24.7B | Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHDNCT05722912expanded access | — | Approved for marketing | Drug: Ruxolitinib | Graft-versus-host Disease (GVHD) | — | — | — | — | 2023-02-10 |
| FATE | Fate Therapeutics | $307M | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesNCT02743351results2023-02-08Percentage of Participants With Cumulative Incidence of Grade II to IV aGvHD Through Day +100 Based on Investigator Assessment | Phase 1/2 | Completed | Biological: ProTmune, Control Arm | Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease | 96 | 2016-12-20 | 2020-12-04actual | — | 2023-02-08 |
| OCGN | Ocugen | $454M | Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host DiseaseNCT03591874results2022-07-06Change From Baseline to Day 84 in Validated Bulbar Redness (VBR) Score | Phase 3 | Terminatedsponsor's stated reason: Primary endpoint was not met. | Drug: Brimonidine Tartrate, Placebos | Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease | 59 | 2018-12-23 | 2020-04-30actual | — | 2022-07-06 |
| INCY | Incyte Corporation | $24.7B | An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantNCT03147742expanded access | — | Approved for marketing | Drug: Ruxolitinib | Graft-versus-host Disease (GVHD) | — | — | — | — | 2022-06-07 |
| MESO | Mesoblast, Inc. | — | Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)NCT00366145Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration | Phase 3 | Completed | Biological: Prochymal® · Drug: Placebo, Standard of Care for GVHD | Graft Versus Host Disease | 260 | 2006-08-17 | 2008-12-26actual | — | 2022-02-10 |
| MESO | Mesoblast, Inc. | — | Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)NCT00562497Percentage of Participants with Treatment Success | Phase 3 | Completed | Drug: Prochymal® · Other: Placebo, Corticosteroid | Graft Versus Host Disease | 192 | 2008-01-31 | 2009-07-14actual | — | 2022-01-19 |
| INCY | Incyte Corporation | $24.7B | A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)NCT02953678results2019-08-20Overall Response Rate (ORR) at Day 28 | Phase 2 | Completed | Drug: Ruxolitinib, Prednisone or methylprednisolone | Graft-versus-host Disease (GVHD) | 71 | 2016-12-30 | 2018-01-31actual | — | 2021-11-24 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)NCT03339297results2021-08-18Cumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 Post-Hematopoietic Stem Cell Transplant (HSCT) | Phase 2 | Completed | Drug: Defibrotide, Standard of Care | Graft-versus-host Disease, Acute-graft-versus-host Disease | 152 | 2018-02-21 | 2020-05-12actual | — | 2021-08-18 |
| MESO | Mesoblast, Inc. | — | Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHDNCT00759018expanded access | — | No longer available | Biological: remestemcel-L | Graft vs Host Disease, Graft-Versus-Host Disease | — | — | — | — | 2020-03-09 |
| MESO | Mesoblast, Inc. | — | Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)NCT00826046expanded access | — | No longer available | Drug: Prochymal® | Graft-Versus-Host Disease | — | — | — | — | 2020-03-09 |
| INCY | Incyte Corporation | $24.7B | Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese SubjectsNCT03497273Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: Itacitinib, Corticosteroid | Acute Graft-versus-host Disease | 14 | 2018-03-20 | 2019-11-30actual | — | 2020-03-03 |
| INCY | Incyte Corporation | $24.7B | Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDNCT02614612Assess safety and tolerability of study treatment as measured by the frequency and severity of adverse events and serious adverse events | Phase 1 | Completed | Drug: Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids) | Graft-versus-host Disease (GVHD) | 31 | Dec 2015 | Jun 2016actual | — | 2019-03-08 |
| GILD | Gilead Sciences | $177.9B | Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)NCT02701634results2018-12-26Best Overall Response Rate | Phase 2 | Terminated | Drug: ENTO, Placebo | Chronic Graft Versus Host Disease | 66 | 2016-05-27 | 2017-12-19actual | — | 2018-12-26 |
| RIGL | Rigel Pharmaceuticals | $815M | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)NCT02040623results2016-10-10Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. | Phase 2 | Completed | Drug: R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5% · Other: Placebo Ophthalmic Solution | Chronic Graft-versus-host Disease | 35 | Mar 2014 | Jul 2016actual | — | 2016-10-10 |
| SOBI.ST | Swedish Orphan Biovitrum | — | Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) TransplantationNCT00189488results2014-09-15Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD) | Phase 2 | Completed | Drug: Palifermin, Placebo, Methotrexate · Other: Conditioning Regimen · Procedure: Allogeneic stem cell transplant | Graft Versus Host Disease, Hematologic Malignancies | 155 | Dec 2005 | Nov 2008actual | — | 2014-09-15 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-NCT00189748 | Phase 2 | Completed | Drug: Tacrolimus | Bone Marrow Transplantation, Graft Versus Host Disease, Graft-Versus-Host Disease, Graft-Vs-Host Disease | — | Aug 2004 | — | — | 2006-09-20 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT RecipientsNCT00189761 | Phase 2 | Completed | Drug: Tacrolimus | Bone Marrow Transplantation, Graft Versus Host Disease, Graft-Vs-Host Disease, Graft-Versus-Host Disease | — | — | — | — | 2006-09-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Graft-Versus-Host Disease is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Chronic Graft Versus Host Disease
- Graft Versus Host Disease
- Chronic Graft-versus-host-disease
- Graft-versus-host Disease (GVHD)
- Graft-Versus-Host Disease
- Acute Graft-versus-host Disease
- Acute-graft-versus-host Disease
- Chronic Graft-versus-host Disease
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Graft-Versus-Host Disease” (a text search, wider than this page)